Beyond the Scale: Visceral Fat, Muscle and Metabolic Health
Successful weight management is about much more than making the number on the scale smaller.
Two people can weigh exactly the same but have very different amounts of visceral fat, skeletal muscle and metabolic risk. At Snatched Aesthetic Wellness, our goal is to help patients reduce unhealthy visceral fat while preserving—and ideally building—the skeletal muscle that supports strength, glucose control and healthy aging.
That is why we measure body composition throughout treatment.
Why Visceral Fat Matters
Subcutaneous fat is stored beneath the skin. Visceral fat is stored deeper within the abdomen, surrounding the internal organs.
Excess visceral fat is more metabolically active and is associated with:
Insulin resistance and type 2 diabetes
High triglycerides and low HDL cholesterol
Hypertension and cardiovascular disease
Metabolic dysfunction-associated fatty-liver disease
Chronic inflammation
Metabolic syndrome
Reducing visceral fat is generally associated with improvements in insulin sensitivity, glucose control and overall cardiometabolic health. However, no body-composition measurement should be interpreted by itself.
We consider visceral fat alongside waist circumference, blood pressure, glucose, hemoglobin A1c, insulin resistance, cholesterol, triglycerides, liver markers and the patient’s overall health.
How Much Visceral Fat Is Too Much?
There is no single universally accepted “dangerous” visceral-fat number. Results vary according to age, sex, ethnicity, body size, metabolic health, scanner manufacturer and whether visceral fat is reported as mass, volume or cross-sectional area.
Research provides some useful reference points:
Visceral-fat area of approximately 100 cm² or greater has been associated with increased metabolic risk.
Measurements around 160 cm² or greater have historically been considered particularly elevated.
A systematic review found that proposed higher-risk thresholds varied from approximately 70 to 166 cm² across different populations.
Some DEXA reports provide visceral fat as a weight. In one large population study of adults aged 40–84, the amounts most predictive of metabolic syndrome were approximately:
Women: 2 pounds 8 ounces
Men: 4 pounds 2 ounces
These are research-based reference points—not universal cutoffs. Published thresholds vary substantially between populations and scanners.
For most patients, the most meaningful objective is a consistent reduction in visceral fat accompanied by improvements in metabolic health—not chasing one supposedly perfect number.
Muscle Is a Metabolic Storage Organ
Skeletal muscle does much more than provide strength and movement. It plays a central role in managing the glucose that enters the bloodstream after a meal.
After eating carbohydrates, insulin helps move much of that glucose into skeletal muscle. The muscle can then:
Use the glucose immediately for energy
Store it as glycogen for future activity
Help prevent excessive post-meal glucose and insulin elevations
In healthy individuals, skeletal muscle accounts for approximately 70–80% of insulin-stimulated glucose disposal. More active, insulin-sensitive muscle provides the body with a larger metabolic “storage tank” for glucose.
When muscle mass is low, physical activity is limited or the muscle becomes insulin resistant, glucose cannot be cleared as efficiently. The pancreas may compensate by producing more insulin, while an insulin-resistant liver may continue releasing glucose when it should be reducing its output.
Over time, this combination can contribute to:
Elevated blood glucose
Chronically elevated insulin
Higher triglycerides
Increasing liver fat
Prediabetes and type 2 diabetes
Glucose regulation involves the muscle, liver, pancreas and adipose tissue working together. Preserving and building functional muscle gives the body a larger, healthier place to store and use glucose and can reduce the metabolic burden created by poor glucose disposal.
Muscle Also Uses Fat for Energy
Muscle cells contain mitochondria that oxidize fatty acids to produce energy. This happens throughout the day and becomes particularly important during sustained lower-to-moderate-intensity physical activity.
Regular resistance and aerobic exercise can improve the muscle’s ability to:
Take up glucose
Store glycogen
Oxidize fatty acids
Respond appropriately to insulin
Switch efficiently between glucose and fat for fuel
Perform more physical work
Building muscle does not automatically melt away body fat, and each additional pound of muscle produces only a modest increase in resting calorie expenditure.
The greater benefit is that stronger, better-trained muscle improves glucose handling, increases exercise capacity and provides more metabolically active tissue capable of using both glucose and fat as energy.
Why Muscle Preservation Matters During Weight Loss
Significant weight loss can include the loss of both fat and lean tissue. This applies to lifestyle-based weight loss as well as treatment with semaglutide, tirzepatide and other GLP-1 or incretin medications.
Clinical body-composition studies of semaglutide and tirzepatide found substantial reductions in total and visceral fat, but they also documented some reduction in lean mass.
This does not mean GLP-1 medications inherently damage muscle. Some lean-tissue loss commonly accompanies substantial weight loss regardless of the method used. It does mean that treatment should focus on body composition—not weight alone.
Our strategy may include:
Adequate daily protein
Progressive resistance training
Regular aerobic activity
Appropriate calorie intake
Correction of clinically significant hormonal or metabolic deficiencies when indicated
Periodic strength and body-composition assessments
Individualized medical monitoring
A lower weight accompanied by excessive muscle loss is not our preferred outcome. We want visceral fat decreasing while muscle, strength and physical performance are preserved or improved.
How We Track Body Composition at Snatched
At Snatched, we use ShapeScale as a quick and convenient way to monitor body composition over time.
ShapeScale produces a three-dimensional image and estimates changes in body fat, visceral fat, lean mass and body measurements. It can also help patients visualize changes that may not be obvious from weight alone.
ShapeScale is not perfect and does not replace DEXA, but its measurements correlate well with DEXA and make it a useful tool for following trends between more comprehensive scans.
ShapeScale testing is included for our patients at no additional charge.
During active body-composition transformation, we recommend obtaining a DEXA scan once or twice per year to confirm changes in visceral fat and skeletal muscle. After reaching a stable maintenance phase, we generally recommend a DEXA once per year.
Whenever possible, follow-up DEXA scans should be performed on the same machine and under similar hydration, meal and exercise conditions.
Together, ShapeScale and periodic DEXA testing help us determine whether treatment is:
Reducing visceral fat
Preserving or increasing skeletal muscle
Improving regional muscle balance
Decreasing waist circumference
Producing a healthier ratio of fat to lean tissue
Creating progress that can be maintained
A whole-body body-composition DEXA does not replace a physician-ordered diagnostic hip-and-spine DEXA used to evaluate osteoporosis.
The Real Goal
The scale tells us how much you weigh. It does not tell us what that weight is made of or where it is stored.
Successful metabolic treatment should produce more than weight loss. We want to see:
Visceral fat trending downward
Skeletal muscle preserved or increasing
Strength and physical performance improving
Glucose, insulin and lipid markers improving
Better long-term metabolic resilience
By combining medical treatment, nutrition, protein intake, resistance training, ShapeScale monitoring and periodic DEXA testing, we can focus on what matters most: helping patients become leaner, stronger and metabolically healthier—not simply lighter.
References
Bennett JP, et al. “Evaluation of Visceral Adipose Tissue Thresholds for Elevated Metabolic Syndrome Risk Across Diverse Populations: A Systematic Review.” Obesity Reviews. 2024. DOI (https://doi.org/10.1111/obr.13767)
Lundblad MW, et al. “Reference Values for DXA-Derived Visceral Adipose Tissue in Adults 40 Years and Older from a European Population: The Tromsø Study 2015–2016.” Journal of Obesity. 2021. Full article and DOI (https://doi.org/10.1155/2021/6634536)
Bea JW, et al. “MRI Based Validation of Abdominal Adipose Tissue Measurements from Historical DXA Scans.” Journal of Clinical Densitometry. 2022. PubMed (https://pubmed.ncbi.nlm.nih.gov/34404568/)
Merz KE, Thurmond DC. “Role of Skeletal Muscle in Insulin Resistance and Glucose Uptake.” Comprehensive Physiology. 2020. Full article (https://pmc.ncbi.nlm.nih.gov/articles/PMC8074531/)
DeFronzo RA, Tripathy D. “Skeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes.” Diabetes Care. 2009. Full article (https://pmc.ncbi.nlm.nih.gov/articles/PMC2811436/)
Wilding JPH, et al. “Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study.” Journal of the Endocrine Society. 2021. Full article (https://pmc.ncbi.nlm.nih.gov/articles/PMC8089287/)
Look M, et al. “Body Composition Changes During Weight Reduction with Tirzepatide in the SURMOUNT-1 Study of Adults with Obesity or Overweight.” Diabetes, Obesity and Metabolism. 2025. PubMed (https://pubmed.ncbi.nlm.nih.gov/39996356/)
ShapeScale. “ShapeScale: Optical 3D Body Scanning for Body Fat Percentage Estimation.” Manufacturer-reported validation against GE Lunar iDXA. Technical summary (https://business.shapescale.com/content/posts/shapescale-optical-3d-body-scanning-for-body-fat-percentage-estimation)
Qiao C, et al. “Prediction of Total and Regional Body Composition from 3D Body Shape.” 2024. This independent study evaluated three-dimensional optical imaging rather than ShapeScale specifically. Full article (https://pmc.ncbi.nlm.nih.gov/articles/PMC11500346/)
